Saponins from Saponaria officinalis L. Augment the Efficacy of a Rituximab-Immunotoxin

Abstract Triterpenoidal saponins are synthesized in the roots of Saponaria officinalis L. The same plant is also a source for the toxin Saporin, which is a ribosome-inactivating protein. Triterpenoidal saponins are known to increase the cytotoxicity of Saporin by modulating its intracellular trafficking. Here, we investigated if the combinatorial effects elicited by purified saponins and Saporin can be applied to increase the therapeutic efficacy of the immunotoxin Saporin-Rituximab. First, saponins were purified by high-performance liquid chromatography. Thereafter, their intrinsic cytotoxicity was evaluated on Ramos cells with no observed effect up to 5 µg/mL, however, saponins increased the cytotoxicity of Saporin, while no influence was observed on its N-glycosidase activity. Saporin-Rituximab bound to CD20 in Ramos cells and, in the absence of saponins, had a GI50 (concentration inhibiting cell growth to 50 %) of 7 nM. However, in the presence of a nontoxic concentration of saponins, the GI50 of Saporin-Rituximab was 0.01 nM, a nearly 700-fold increase in efficacy. Moreover, two further immunotoxins, namely Saporin-anti-CD22 and Saporin-anti-CD25, were tested in combination with saponins yielding enhancement factors of 170-fold and 25-fold, respectively. All three receptors are present in Ramos cells and the differences in cytotoxicity enhancement may be explained by the differing expression levels of the cellular receptors. The application of purified saponins from S. officinalis L. is therefore a new strategy to potentially improve the cytotoxicity and therapeutic efficacy of Rituximab-immunotoxins for the treatment of B-cell lymphoma.

[1]  Ł. Pecio,et al.  Highly Polar Triterpenoid Saponins from the Roots of Saponaria officinalis L , 2016 .

[2]  M. Melzig,et al.  Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent , 2015, Immunopharmacology and immunotoxicology.

[3]  M. Melzig,et al.  Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy , 2014, Current pharmaceutical design.

[4]  I. Jacobs,et al.  Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey , 2014, Pharmaceuticals.

[5]  B. Wiesner,et al.  Reporter Assay for Endo/Lysosomal Escape of Toxin-Based Therapeutics , 2014, Toxins.

[6]  I. Pastan,et al.  Immunotoxins for leukemia. , 2014, Blood.

[7]  G. Marti,et al.  Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia. , 2013, American journal of clinical pathology.

[8]  T. Hug,et al.  Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells. , 2013, Molecular pharmaceutics.

[9]  B. Wiesner,et al.  Macromolecular interactions of triterpenoids and targeted toxins: role of saponins charge. , 2013, International journal of biological macromolecules.

[10]  L. Polito,et al.  Saporin-S6: A Useful Tool in Cancer Therapy , 2013, Toxins.

[11]  A. Weng,et al.  Small structural differences of targeted anti-tumor toxins result in strong variation of protein expression. , 2013, Protein expression and purification.

[12]  M. Melzig,et al.  Real-time analysis of membrane permeabilizing effects of oleanane saponins. , 2013, Bioorganic & medicinal chemistry.

[13]  M. Melzig,et al.  Saponins modulate the intracellular trafficking of protein toxins. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Melzig,et al.  The toxin component of targeted anti‐tumor toxins determines their efficacy increase by saponins , 2012, Molecular oncology.

[15]  Mayank Thakur,et al.  Real time monitoring of the cell viability during treatment with tumor-targeted toxins and saponins using impedance measurement. , 2012, Biosensors & bioelectronics.

[16]  M. Melzig,et al.  Triterpenoid saponins of the Caryophyllaceae and Illecebraceae family , 2010 .

[17]  P. Schmieder,et al.  A convenient method for saponin isolation in tumour therapy. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[18]  Mitchell R. Smith,et al.  Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. , 2010, P & T : a peer-reviewed journal for formulary management.

[19]  M. Czuczman,et al.  Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms , 2010, Immunologic research.

[20]  I. Pastan,et al.  Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. , 2008, Cancer research.

[21]  G. Packham,et al.  Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling* , 2008, Journal of Biological Chemistry.

[22]  P. Greenberg,et al.  Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1 , 2008, The Journal of Immunology.

[23]  G. Mazza,et al.  Saponins: Properties, Applications and Processing , 2007, Critical reviews in food science and nutrition.

[24]  J. Vincken,et al.  Saponins, classification and occurrence in the plant kingdom. , 2007, Phytochemistry.

[25]  M. Pescovitz Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  L. Polito,et al.  The conjugate Rituximab/saporin-S6 completely inhibits clonogenic growth of CD20-expressing cells and produces a synergistic toxic effect with Fludarabine , 2004, Leukemia.

[27]  I. Heisler,et al.  A cleavable adapter to reduce nonspecific cytotoxicity of recombinant immunotoxins , 2003, International journal of cancer.

[28]  K. Becker,et al.  The biological action of saponins in animal systems: a review. , 2002, The British journal of nutrition.

[29]  E. Vitetta,et al.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.

[30]  F. Stivala,et al.  Understanding rituximab function and resistance: implications for tailored therapy. , 2011, Frontiers in bioscience.